Benitec Biopharma will participate in investor conferences on December 4 and December 12, 2024, in New York.
Quiver AI Summary
Benitec Biopharma Inc., a biotechnology company based in Hayward, California, focused on developing genetic therapies using its unique "Silence and Replace" DNA-directed RNA interference platform, has announced its participation in two upcoming investor conferences. The first event is the Piper Sandler Annual Healthcare Conference on December 4, 2024, featuring a fireside discussion and one-on-one meetings in New York City. The second event is the Oppenheimer Movers in Rare Disease Summit on December 12, 2024, which will include a panel discussion and one-on-one meetings. Benitec is advancing therapeutics for chronic and life-threatening diseases, including Oculopharyngeal Muscular Dystrophy (OPMD), and interested parties can view the presentations via live webcast. Further details about the company are available on its website.
Potential Positives
- Participation in high-profile investor conferences enhances visibility and credibility within the biotechnology sector.
- The focus on rare diseases positions Benitec as a potential leader in addressing unmet medical needs.
- The "Silence and Replace" ddRNAi platform demonstrates innovation in genetic medicine, which may attract investor interest and confidence.
Potential Negatives
- Participation in investor conferences may suggest the company is seeking to improve investor confidence amidst potential challenges in securing funding or advancing its clinical programs.
- The announcement of upcoming investor conferences does not include any new significant data or advancements in the company's developmental pipeline, which could lead to concerns about stagnation in progress.
- The focus on meetings and discussions may imply a need for external engagement to bolster interest, rather than showcasing significant breakthroughs or market successes.
FAQ
What conferences is Benitec Biopharma attending?
Benitec Biopharma will attend the Piper Sandler Annual Healthcare Conference and the Oppenheimer Movers in Rare Disease Summit.
When will Benitec's fireside discussions occur?
The fireside discussion at the Piper Sandler conference is on December 4, 2024, and at the Oppenheimer summit on December 12, 2024.
Where is Benitec's headquarters located?
Benitec Biopharma is headquartered in Hayward, California.
What is Benitec's main focus in biotechnology?
Benitec focuses on developing novel genetic medicines using its proprietary "Silence and Replace" DNA-directed RNA interference platform.
How can investors schedule meetings with Benitec management?
Investors can contact their conference representative to schedule a 1x1 meeting with Benitec management during the conferences.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$BNTC Insider Trading Activity
$BNTC insiders have traded $BNTC stock on the open market 4 times in the past 6 months. Of those trades, 4 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $BNTC stock by insiders over the last 6 months:
- CAPITAL MANAGEMENT, LLC SUVRETTA has traded it 4 times. They made 4 purchases, buying 41,436 shares and 0 sales.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$BNTC Hedge Fund Activity
We have seen 13 institutional investors add shares of $BNTC stock to their portfolio, and 8 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- SUVRETTA CAPITAL MANAGEMENT, LLC added 7,137,763 shares (+422.0%) to their portfolio in Q3 2024
- NANTAHALA CAPITAL MANAGEMENT, LLC added 838,095 shares (+inf%) to their portfolio in Q3 2024
- SIMPLIFY ASSET MANAGEMENT INC. added 65,319 shares (+127.5%) to their portfolio in Q3 2024
- ARMISTICE CAPITAL, LLC added 60,000 shares (+inf%) to their portfolio in Q3 2024
- LION POINT CAPITAL, LP added 39,000 shares (+inf%) to their portfolio in Q3 2024
- ACUTA CAPITAL PARTNERS, LLC added 29,800 shares (+inf%) to their portfolio in Q3 2024
- JANUS HENDERSON GROUP PLC removed 24,293 shares (-2.7%) from their portfolio in Q3 2024
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
HAYWARD, Calif., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or the “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary “Silence and Replace” DNA-directed RNA interference ("ddRNAi") platform, today announced that its management team will participate in the following upcoming investor conferences.
Piper Sandler Annual Healthcare Conference
Date:
December 4, 2024
Time of Fireside Discussion:
12:00 PM EST
Location:
New York, NY
Format:
Fireside Discussion & 1x1 Meetings
The Benitec presentation will also be available via live webcast here .
Oppenheimer Movers in Rare Disease Summit
Date:
December 12, 2024
Time of Fireside Chat:
9:50-10:40 AM EST
Location:
New York, NY
Format:
Panel discussion & 1x1 Meetings
Please contact your conference representative to schedule a 1x1 meeting with Benitec management.
About
Benitec
Biopharma
Inc.
Benitec Biopharma Inc. (“Benitec” or the “Company”) is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines with headquarters in Hayward, California. The proprietary “Silence and Replace” DNA-directed RNA interference platform combines RNA interference, or RNAi, with gene therapy to create medicines that simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct. The Company is developing Silence and Replace-based therapeutics for chronic and life-threatening human conditions including Oculopharyngeal Muscular Dystrophy (OPMD). A comprehensive overview of the Company can be found on Benitec’s website at
www.benitec.com
.
Investor
Relations
Contact:
Irina Koffler
LifeSci Advisors
Tel: (917) 734-7387
[email protected]
